Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242316749 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von George J Kontoghiorghes. Beteiligte Einrichtung: Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol 3021, Cyprus. Hauptthemen laut MEDLINE: Iron Overload, beta-Thalassemia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 321 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Postgraduate Research Institute of Science, Technology, Environment and Medicine.
Abstract (Originalsprache)
The design of clinical protocols and the selection of drugs with appropriate posology are critical parameters for therapeutic outcomes. Optimal therapeutic protocols could ideally be designed in all diseases including for millions of patients affected by excess iron deposition (EID) toxicity based on personalised medicine parameters, as well as many variations and limitations. EID is an adverse prognostic factor for all diseases and especially for millions of chronically red-blood-cell-transfused patients. Differences in iron chelation therapy posology cause disappointing results in neurodegenerative diseases at low doses, but lifesaving outcomes in thalassemia major (TM) when using higher doses. In particular, the transformation of TM from a fatal to a chronic disease has been achieved using effective doses of oral deferiprone (L1), which improved compliance and cleared excess toxic iron from the heart associated with increased mortality in TM. Furthermore, effective L1 and L1/deferoxamine combination posology resulted in the complete elimination of EID and the maintenance of normal iron store levels in TM. The selection of effective chelation protocols has been monitored by MRI T2* diagnosis for EID levels in different organs. Millions of other iron-loaded patients with sickle cell anemia, myelodysplasia and haemopoietic stem cell transplantation, or non-iron-loaded categories with EID in different organs could also benefit from such chelation therapy advances. Drawbacks of chelation therapy include drug toxicity in some patients and also the wide use of suboptimal chelation protocols, resulting in ineffective therapies. Drug metabolic effects, and interactions with other metals, drugs and dietary molecules also affected iron chelation therapy. Drug selection and the identification of effective or optimal dose protocols are essential for positive therapeutic outcomes in the use of chelating drugs in TM and other iron-loaded and non-iron-loaded conditions, as well as general iron toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol 3021, Cyprus.
ORCID-Profile: George J Kontoghiorghes
Förderung
- Postgraduate Research Institute of Science, Technology, Environment and Medicine
Zitieren
APA
Kontoghiorghes, G. J. (2023). Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316749
Vancouver
Kontoghiorghes GJ. Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242316749
BibTeX
@article{Kontoghiorghes2023,
author = {Kontoghiorghes, George J},
title = {Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242316749}
}
EUVIMED